Skip to main content
Top
Published in: Pathology & Oncology Research 1/2019

01-01-2019 | Original Article

Long Non-Coding RNA SPRY4-IT1 Can Predict Poor Prognosis in Digestive System Malignancies: a Meta-Analysis

Authors: Cheng Sun, Yangyang Ding, Shimin Wang, Wei Hu

Published in: Pathology & Oncology Research | Issue 1/2019

Login to get access

Abstract

Recent studies have reported that long non-coding RNA SPRY4 intron transcript 1 (SPRY4-IT1) is abnormally expressed in malignant digestive tumors and associated with prognosis. But its clinical relevance is unclear. Here, we performed a meta-analysis aims to evaluate the prognostic value of SPRY4-IT1 in digestive system malignancies. We systematic search the PubMed, Web of Science, ScienceDirect and Wiley Online Library database to eligible studies. The pooled hazard ratios (HRs) with a 95% confidence interval (95% CI) were calculated to explored the association of lncRNA SPRY4-IT1 with prognosis. Five studies were eligible for analysis, a total of 518 patients were included. Meta-analysis indicated that overexpression of SPRY4-IT1 was associated with poor over survival (OS) (HR = 1.24, 95%CI:0.49–1.98; random-effects model). The clinicopathological parameters analysis further showed that increased expression level of SPRY4-IT1 was positively correlated with lymph node metastasis (HR = 1.45, 95% CI =0.88–2.02; fixed-effects model), TNM stage (HR = 1.24,95% CI = 0.78–1.70; fixed-effects model), and invasion depth (HR = 1.25,95% CI = 0.63–1.88; fixed-effects model). lncRNA SPRY4-IT1 may serve as a potential prognostic marker in malignant digestive tumors.
Literature
1.
go back to reference Garzon R, Volinia S, Papaioannou D et al (2014) Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A 111:18679–18684CrossRefPubMedPubMedCentral Garzon R, Volinia S, Papaioannou D et al (2014) Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A 111:18679–18684CrossRefPubMedPubMedCentral
2.
go back to reference Kim SH, Lee HW, Go SI, Lee SI, Lee GW (2016) Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget 7:36198–36206PubMedPubMedCentral Kim SH, Lee HW, Go SI, Lee SI, Lee GW (2016) Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Oncotarget 7:36198–36206PubMedPubMedCentral
3.
go back to reference Chan JC, Chan DL, Diakos CI et al (2016) The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 265(3):539–546 Chan JC, Chan DL, Diakos CI et al (2016) The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 265(3):539–546
5.
go back to reference Zarate R, Boni V, Bandres E, Garcia-Foncillas J (2012) MiRNAs and LincRNAs: could they be considered as biomarkers in colorectal cancer? Int J Mol Sci 13:840–865CrossRefPubMedPubMedCentral Zarate R, Boni V, Bandres E, Garcia-Foncillas J (2012) MiRNAs and LincRNAs: could they be considered as biomarkers in colorectal cancer? Int J Mol Sci 13:840–865CrossRefPubMedPubMedCentral
7.
go back to reference Sugihara H, Ishimoto T, Miyake K et al (2015) Noncoding RNA expression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma. Int J Mol Sci 16:27824–27834CrossRefPubMedPubMedCentral Sugihara H, Ishimoto T, Miyake K et al (2015) Noncoding RNA expression aberration is associated with cancer progression and is a potential biomarker in esophageal squamous cell carcinoma. Int J Mol Sci 16:27824–27834CrossRefPubMedPubMedCentral
9.
go back to reference Cao D, Ding Q, Yu W, Gao M, Wang Y (2016) Long noncoding RNA SPRY4-IT1 promotes malignant development of colorectal cancer by targeting epithelial-mesenchymal transition. Onco Targets Ther 9:5417–5425CrossRefPubMedPubMedCentral Cao D, Ding Q, Yu W, Gao M, Wang Y (2016) Long noncoding RNA SPRY4-IT1 promotes malignant development of colorectal cancer by targeting epithelial-mesenchymal transition. Onco Targets Ther 9:5417–5425CrossRefPubMedPubMedCentral
10.
11.
go back to reference Peng W, Wu G, Fan H, Wu J, Feng J (2015) Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour Bio l36:6751–6758 Peng W, Wu G, Fan H, Wu J, Feng J (2015) Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour Bio l36:6751–6758
12.
go back to reference Xie M, F-q N, Sun M et al (2015) Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial-mesenchymal transition. J Transl Med 13:250CrossRefPubMedPubMedCentral Xie M, F-q N, Sun M et al (2015) Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelial-mesenchymal transition. J Transl Med 13:250CrossRefPubMedPubMedCentral
13.
go back to reference Xie H-W, Wu Q-Q, Zhu B et al (2014) Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumor Biol 35:7743–7754CrossRef Xie H-W, Wu Q-Q, Zhu B et al (2014) Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumor Biol 35:7743–7754CrossRef
14.
go back to reference Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRefPubMed
16.
go back to reference Jin K, Luo G, Xiao Z et al (2015) Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Dev Ther 9:1247–1255CrossRef Jin K, Luo G, Xiao Z et al (2015) Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Dev Ther 9:1247–1255CrossRef
17.
go back to reference Khaitan D, Dinger ME, Mazar J et al (2011) The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 71:3852–3862CrossRefPubMed Khaitan D, Dinger ME, Mazar J et al (2011) The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 71:3852–3862CrossRefPubMed
18.
go back to reference Sun M, Liu XH, Lu KH et al (2014) EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis 5:e1298CrossRefPubMedPubMedCentral Sun M, Liu XH, Lu KH et al (2014) EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis 5:e1298CrossRefPubMedPubMedCentral
19.
go back to reference Shi Y, Li J, Liu Y et al (2015) The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol Cancer 14:51CrossRefPubMedPubMedCentral Shi Y, Li J, Liu Y et al (2015) The long noncoding RNA SPRY4-IT1 increases the proliferation of human breast cancer cells by upregulating ZNF703 expression. Mol Cancer 14:51CrossRefPubMedPubMedCentral
Metadata
Title
Long Non-Coding RNA SPRY4-IT1 Can Predict Poor Prognosis in Digestive System Malignancies: a Meta-Analysis
Authors
Cheng Sun
Yangyang Ding
Shimin Wang
Wei Hu
Publication date
01-01-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0327-y

Other articles of this Issue 1/2019

Pathology & Oncology Research 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine